Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award

Associate Professor from Department of Physiology, China Medical University, Taiwan

Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.

Professional Profile

Education

Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.

Professional Experience

Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.

Research Interests

Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.

Research Skills

Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.

Awards and Honors

Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.

Conclusion

Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.

Publication Top Notes

M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025

2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025

3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025

4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024

5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024

6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2

7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2

Rashna Mirza | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Ms. Rashna Mirza | Pharmaceutical Science | Best Researcher Award

PhD scholar of Quaid-i-Azam University, Pakistan.

Rashna Mirza is a distinguished researcher currently pursuing a PhD at Quaid-i-Azam University, Islamabad, focusing on advanced drug delivery systems, including brain-targeted transfersomes and optimized nano-transfersomes. A Gold Medalist in Pharm D from People’s University of Medical and Health Sciences for Women, she has demonstrated exceptional academic and research prowess. Her professional experience includes roles in quality assurance, pharmaceutical research, and laboratory supervision, showcasing her expertise in drug formulation and optimization. Rashna’s commitment to the field is reflected in her impactful publications and active participation in conferences. Her strengths lie in cutting-edge research, scientific communication, and organizational skills, though expanding her research impact and gaining leadership experience could further enhance her profile. Rashna’s background and achievements make her a strong candidate for the Research for Best Researcher Award.

Profile

Education

Rashna Mirza’s educational background reflects her strong commitment to the field of pharmaceutics. She is currently pursuing a PhD at Quaid-i-Azam University, Islamabad, with research focused on advanced drug delivery systems, including brain targeting of Cefepime-loaded transfersomes and optimization of nano-transfersomes for transdermal delivery. Prior to her PhD, Rashna completed her M.Phil at the same institution, where she continued to build on her expertise in pharmaceutics. She earned her Pharm D from People’s University of Medical and Health Sciences for Women, where she graduated as a Gold Medalist, underscoring her exceptional academic performance. Rashna’s foundational education includes an FSC Pre-Medical from Government Girls Degree College, Islamabad, and matriculation from Foundation Public School, Karachi. This robust educational background has equipped her with a deep understanding of pharmaceutical sciences and a solid foundation for her research career.

Professional Experience

Rashna Mirza has a diverse professional background that underscores her expertise in pharmaceutics and drug development. Currently pursuing her PhD at Quaid-i-Azam University, she is engaged in pioneering research on brain-targeted drug delivery systems and transdermal gels. Her experience includes working as a Lab Demonstrator at Quaid-i-Azam University, where she managed laboratory work, supervised experiments, and facilitated instructional activities. She also served as a Quality Assurance Inspector at Herbiotics, where she conducted inspections, quality audits, and process monitoring. Additionally, Rashna worked as a Retail Pharmacist at Punjab Pharmacy, handling inventory management, patient counseling, and medication therapy management. Her academic journey is marked by her gold medal achievement in Pharm D from People’s University of Medical and Health Sciences for Women. Her professional roles reflect her strong organizational, supervisory, and research skills, contributing significantly to her field.

Research Interest

Rashna Mirza’s research interests center on the development and optimization of novel drug delivery systems to enhance therapeutic outcomes. Her current PhD research focuses on innovative approaches such as brain-targeting of Cefepime-loaded transfersomes and the formulation of nano-transfersomes-based chitosan gels for transdermal delivery. This work aims to improve drug efficacy and patient compliance through advanced delivery mechanisms. Rashna is also interested in the formulation and optimization of thermosensitive in situ gels, exploring their potential for controlled and targeted drug release. Her research integrates both in vitro and in vivo studies to address challenges in pharmaceutical science, emphasizing the importance of precise drug delivery for effective treatment. Rashna’s work is characterized by a commitment to advancing pharmaceutics through rigorous experimentation and collaboration, contributing valuable insights to the field and aiming to bridge gaps in current drug delivery technologies.

Research Skills

Rashna Mirza exhibits a strong suite of research skills that underscore her capabilities in advancing the field of pharmaceutics. Her expertise in drug formulation and optimization is evident through her current PhD research, which involves innovative drug delivery systems such as brain-targeting transfersomes and nano-transfersomes. Rashna’s proficiency in statistical design and optimization further enhances her ability to develop and refine novel drug delivery methods. Her hands-on laboratory skills are complemented by her experience in quality assurance and process monitoring, ensuring meticulous evaluation and control of research processes. Additionally, Rashna’s solid background in scientific communication and report writing enables her to effectively present and disseminate research findings. Her involvement in interdisciplinary collaboration and active participation in conferences reflects her commitment to integrating diverse perspectives and advancing scientific knowledge. Overall, Rashna’s research skills demonstrate a well-rounded and impactful approach to pharmaceutics and drug development.

Award and Recognition

Rashna Mirza, a distinguished researcher and Gold Medalist in Pharm D, has garnered significant recognition for her contributions to the field of pharmaceutics. Her innovative research on drug delivery systems, including brain-targeting transfersomes and nano-transfersome optimization, has been widely acknowledged within the scientific community. Rashna’s work is prominently featured in impactful publications, reflecting her dedication to advancing drug formulation and optimization. Her role as a Lab Demonstrator and Quality Assurance Inspector highlights her exceptional skills in scientific communication, process improvement, and interdisciplinary collaboration. Additionally, Rashna’s participation in notable conferences and her involvement in quality audits further underscore her commitment to excellence in pharmaceutical research. These achievements collectively affirm her as a leading figure in her field, earning her well-deserved recognition and positioning her as a promising candidate for prestigious awards in pharmaceutics and drug development.

Conclusion

Rashna Mirza’s strong background in pharmaceutics, demonstrated research capabilities, and commitment to advancing drug delivery systems position her as a suitable candidate for the Research for Best Researcher Award. Her strengths in innovative research, academic excellence, and effective communication support her candidacy, while opportunities for broader impact and leadership development could further enhance her profile.

Publication Top Notes

  • Brain targeting of cefepime loaded transfersomes based thermosensitive in situ gel via intranasal delivery: In vitro and in vivo studies
    • Authors: R. Mirza, A.U. Khan, K.U. Shah, F. Alasmari, Z. Hafeez
    • Year: 2024
    • Citations: 1
  • Statistical design and optimization of nano-transfersomes based chitosan gel for transdermal delivery of cefepime
    • Authors: R. Mirza, K.U. Shah, A.U. Khan, Z. Hafeez, S.U. Haq
    • Year: 2024